CytoMed Therapeutics (GDTC) Competitors $2.14 +0.12 (+5.94%) As of 09:43 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock GDTC vs. COYA, ENTX, LXEO, BMEA, ORMP, UNCY, ANIX, CHRS, MIST, and JSPRShould you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include Coya Therapeutics (COYA), Entera Bio (ENTX), Lexeo Therapeutics (LXEO), Biomea Fusion (BMEA), Oramed Pharmaceuticals (ORMP), Unicycive Therapeutics (UNCY), Anixa Biosciences (ANIX), Coherus BioSciences (CHRS), Milestone Pharmaceuticals (MIST), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. CytoMed Therapeutics vs. Its Competitors Coya Therapeutics Entera Bio Lexeo Therapeutics Biomea Fusion Oramed Pharmaceuticals Unicycive Therapeutics Anixa Biosciences Coherus BioSciences Milestone Pharmaceuticals Jasper Therapeutics Coya Therapeutics (NASDAQ:COYA) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Does the MarketBeat Community believe in COYA or GDTC? Coya Therapeutics received 23 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 93.10% of users gave Coya Therapeutics an outperform vote. CompanyUnderperformOutperformCoya TherapeuticsOutperform Votes2793.10% Underperform Votes26.90%CytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo Votes Do institutionals and insiders hold more shares of COYA or GDTC? 39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is COYA or GDTC more profitable? CytoMed Therapeutics' return on equity of 0.00% beat Coya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -31.63% -27.76% CytoMed Therapeutics N/A N/A N/A Do analysts prefer COYA or GDTC? Coya Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 193.10%. CytoMed Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 133.64%. Given Coya Therapeutics' higher possible upside, analysts plainly believe Coya Therapeutics is more favorable than CytoMed Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to COYA or GDTC? In the previous week, Coya Therapeutics had 4 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 5 mentions for Coya Therapeutics and 1 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.89 beat Coya Therapeutics' score of 0.62 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Coya Therapeutics Positive CytoMed Therapeutics Very Positive Which has more risk & volatility, COYA or GDTC? Coya Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500. Which has preferable valuation and earnings, COYA or GDTC? CytoMed Therapeutics has lower revenue, but higher earnings than Coya Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$3.69M26.32-$7.99M-$1.07-5.42CytoMed Therapeutics$69.50K336.85-$3.13MN/AN/A SummaryCoya Therapeutics beats CytoMed Therapeutics on 8 of the 14 factors compared between the two stocks. Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GDTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDTC vs. The Competition Export to ExcelMetricCytoMed TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.41M$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.8527.2320.02Price / Sales336.85256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book2.746.617.124.70Net Income-$3.13M$143.93M$3.23B$247.97M7 Day Performance4.34%3.84%2.74%2.64%1 Month Performance-7.12%11.14%8.94%6.39%1 Year Performance2.88%4.35%31.59%13.95% CytoMed Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDTCCytoMed Therapeutics2.6235 of 5 stars$2.14+5.9%$5.00+133.6%+2.9%$23.41M$69.50K0.00N/ACOYACoya Therapeutics2.2204 of 5 stars$5.65+1.8%$17.00+200.9%-29.6%$94.50M$3.69M-8.696News CoverageAnalyst ForecastENTXEntera Bio1.8719 of 5 stars$2.08+7.0%$10.00+381.9%+0.5%$94.31M$223K-7.9820Positive NewsShort Interest ↑LXEOLexeo Therapeutics3.5463 of 5 stars$2.82+3.7%$18.50+556.0%-74.3%$93.62M$650K-0.8958Positive NewsBMEABiomea Fusion3.0211 of 5 stars$2.49+60.6%$21.40+759.4%-43.6%$93.55MN/A-0.6250Positive NewsHigh Trading VolumeORMPOramed Pharmaceuticals1.8658 of 5 stars$2.26-5.0%N/A+7.7%$92.32M$2M20.5510Positive NewsUNCYUnicycive Therapeutics3.5943 of 5 stars$0.76+15.2%$6.00+686.4%-3.8%$92.04M$680K-0.799News CoverageShort Interest ↓Analyst RevisionGap UpHigh Trading VolumeANIXAnixa Biosciences3.4683 of 5 stars$2.82-2.4%$9.00+219.1%+30.2%$90.80M$210K-7.235Analyst ForecastCHRSCoherus BioSciences4.0014 of 5 stars$0.78+1.8%$4.68+500.4%-53.5%$90.43M$272.25M-9.75330MISTMilestone Pharmaceuticals2.4055 of 5 stars$1.69-2.3%$17.00+905.9%+19.4%$90.35M$1M-2.0930Positive NewsJSPRJasper Therapeutics2.8144 of 5 stars$5.90+8.3%$62.22+954.6%-76.7%$88.63MN/A-1.2420Positive NewsAnalyst Revision Related Companies and Tools Related Companies COYA Competitors ENTX Competitors LXEO Competitors BMEA Competitors ORMP Competitors UNCY Competitors ANIX Competitors CHRS Competitors MIST Competitors JSPR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GDTC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GDTC Stock Free GDTC Stock Alerts